Back to news

Revolution Medicines slips as investors digest recent results and conference updates

Investivoq PriceTracker

Revolution Medicines (RVMD) is down 4.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be profit-taking and a lack of a fresh upside catalyst after investors digested the company’s recent quarterly update and conference remarks. The business update was fundamentally strong, but it also highlighted a very large net loss and a development story that still depends on major 2027 trial readouts, which can invite volatility in biotech names after big prior gains.

Details:

  • In its November 4 quarterly update, the company reported its first meaningful product revenue from RASONQUE after the August launch, showing a strong early commercial start.
  • The same filing also showed a quarterly net loss of more than $400 million, reflecting heavy research spending and non-operating charges tied in part to warrant liability changes.
  • Management said enrollment for a key Phase 3 lung cancer study is winding down with an initial readout expected in 2027, leaving investors waiting for the next major clinical inflection point.
  • The company also appeared at a November investor conference, but there was no obvious new breakthrough announcement beyond previously disclosed launch and pipeline progress, which could have limited buying interest.

    • Sources:

    Revolution Medicines Investor Relations, SEC, Yahoo Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $RVMD Insider Trading Activity

    RVMD Insider Trades

    $RVMD insiders have traded $RVMD stock on the open market 106 times in the past 6 months. Of those trades, 0 have been purchases and 106 have been sales.

    Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

    • MARK A GOLDSMITH (See Remarks) has made 0 purchases and 21 sales selling 110,008 shares for an estimated $22,342,355.
    • STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 11 sales selling 102,275 shares for an estimated $20,486,119.
    • MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 11 sales selling 104,967 shares for an estimated $16,883,735.
    • LORENCE H. KIM has made 0 purchases and 14 sales selling 73,090 shares for an estimated $14,967,124.
    • JEFF CISLINI (SVP & General Counsel) has made 0 purchases and 10 sales selling 63,182 shares for an estimated $13,070,226.
    • ANTHONY MANCINI (See Remarks) has made 0 purchases and 15 sales selling 32,740 shares for an estimated $6,230,991.
    • ELIZABETH M ANDERSON has made 0 purchases and 5 sales selling 10,143 shares for an estimated $1,958,015.
    • ALAN B. SANDLER (Chief Development Officer) has made 0 purchases and 7 sales selling 6,650 shares for an estimated $1,343,234.
    • JACK ANDERS (Chief Financial Officer) has made 0 purchases and 3 sales selling 6,775 shares for an estimated $1,232,469.
    • SUSHIL PATEL has made 0 purchases and 9 sales selling 5,580 shares for an estimated $1,048,967.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive RVMD Data Alerts
    Get market-moving data, filings, and signals for RVMD in real time.
    Sign Up

    $RVMD Hedge Fund Activity

    We have seen 484 institutional investors add shares of $RVMD stock to their portfolio, and 252 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DARWIN GLOBAL MANAGEMENT, LTD. added 8,418,804 shares (+380.8%) to their portfolio in Q2 2026, for an estimated $1,576,673,613
    • ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,878,385 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $913,623,942
    • CAPITAL WORLD INVESTORS added 4,008,244 shares (+inf%) to their portfolio in Q2 2026, for an estimated $750,663,936
    • JPMORGAN CHASE & CO added 3,298,066 shares (+inf%) to their portfolio in Q2 2026, for an estimated $617,661,800
    • FMR LLC added 3,197,292 shares (+26.2%) to their portfolio in Q3 2026, for an estimated $656,276,155
    • BLACKROCK, INC. added 2,483,084 shares (+22.1%) to their portfolio in Q2 2026, for an estimated $465,031,971
    • WELLINGTON MANAGEMENT GROUP LLP removed 2,184,404 shares (-36.2%) from their portfolio in Q2 2026, for an estimated $409,095,181

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $RVMD Price Targets

    Multiple analysts have issued price targets for $RVMD recently. We have seen 10 analysts offer price targets for $RVMD in the last 6 months, with a median target of $202.5.

    Here are some recent targets:

    • Michael Schmidt from Guggenheim set a target price of $235.0 on 07/09/2026
    • Robert Burns from HC Wainwright & Co. set a target price of $195.0 on 07/06/2026
    • Joseph Catanzaro from Mizuho set a target price of $215.0 on 07/06/2026
    • Robert Driscoll from Wedbush set a target price of $181.0 on 07/02/2026
    • Gregory Renza from Truist Securities set a target price of $210.0 on 06/30/2026
    • Ami Fadia from Needham set a target price of $235.0 on 06/29/2026
    • Cory Kasimov from Evercore ISI Group set a target price of $220.0 on 06/10/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.